Skip to Content
Søk Menu

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

HER2-targeted therapy, particularly known for breast cancer treatment, has in recent years gained traction in the treatment of gastroesophageal adenocarcinoma as well. In this article, based on a piece published by ASCO Daily News, we will provide a brief introduction to the developments in this field.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24
Sara Hurvitz

Use of Anthracyclines Should Be Re-Evaluated for Treatment of Breast Cancer

/ Sara A. Hurvitz
BröstcancerOnkologisk Forum 2024 Play the Video 03:12

Another Step Forward for Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24
Hope Rugo

Abemaciclib Shows Significant Benefit for HR-positive HER2-negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Bröstcancer Play the Video 11:57

Nordic Collaboration on Breast Cancer Research Reignited

/ BestPractice Nordic
Bröstcancer
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
BröstcancerESMO24 Play the Video 04:50
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BröstcancerESMO24 Play the Video 4:51
Back to top